Merck KGaA agreed to buy Bio-Techne for approximately $11.3 billion, positioning the combined group to expand life sciences tools, multiomics capabilities, and analytical workflow offerings. The purchase would add Bio-Techne’s portfolio of reagents, assays, and integrated solutions across discovery, translational research, and development. The agreement—at $73 per share—reflects Merck KGaA’s strategic push to broaden its life sciences presence and deepen technology supply for cell therapy developers. Merck KGaA also highlighted expected benefits from Bio-Techne’s cell culture device ownership structure, including a pathway to acquire Wilson Wolf equity exposure. The deal is one of the largest in Merck KGaA’s recent history and will be closely watched for how it affects pricing, manufacturing capacity, and customer bundling across multiomics and spatial biology workflows.